Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 10 articles: HTML format

Single Articles

January 2025
1. ZHENG K, Jin G, Cao R, Gao Y, et al
   Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.
   Cancer Chemother Pharmacol. 2025;95:21.
   PubMed     Abstract available
   
   
   May 2024
2. XU R, Yang X, Tang B, Mao Y, et al
   Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.
   Cancer Chemother Pharmacol. 2024 May 7. doi: 10.1007/s00280-024-04671.
   PubMed     Abstract available
   
   
   April 2024
3. LEE IH, Lee SJ, Kim J, Lee YH, et al
   Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.
   Cancer Chemother Pharmacol. 2024 Apr 23. doi: 10.1007/s00280-024-04670.
   PubMed     Abstract available
   
   
   November 2023
4. WANG Y, Wen J, Sun X, Sun Y, et al
   CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
   Cancer Chemother Pharmacol. 2023 Nov 8. doi: 10.1007/s00280-023-04610.
   PubMed     Abstract available
   
   
   August 2023
5. NWABUFO CK
   Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
   Cancer Chemother Pharmacol. 2023 Aug 18. doi: 10.1007/s00280-023-04575.
   PubMed     Abstract available
   
   
   June 2023
6. KONIG P, Zhulenko R, Suparman E, Hoffmeister H, et al
   A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis.
   Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04548.
   PubMed     Abstract available
   
   
   
7. HONG L, Wang X, Zheng L, Wang S, et al
   Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis.
   Cancer Chemother Pharmacol. 2023 Jun 5. doi: 10.1007/s00280-023-04533.
   PubMed     Abstract available
   
   
   
8. HU C, Zhang Y, Pei T, Liu P, et al
   Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
   Cancer Chemother Pharmacol. 2023;91:523-529.
   PubMed     Abstract available
   
   
   March 2023
9. BAUM J, Zickler D, Bolbrinker J, Richter R, et al
   Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis.
   Cancer Chemother Pharmacol. 2023 Mar 22. doi: 10.1007/s00280-023-04514.
   PubMed     Abstract available
   
   
   
10. DE JONG LAW, Lambert M, van Erp NP, de Vries L, et al
    Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
    Cancer Chemother Pharmacol. 2023 Mar 9. doi: 10.1007/s00280-023-04512.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.